Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Microbes Infect ; 20(6): 369-375, 2018.
Article in English | MEDLINE | ID: mdl-29842985

ABSTRACT

Cryptosporidium spp. are opportunistic protozoan parasites that infect epithelial cells in the intestinal tract and cause a flu-like diarrheal illness. Innate immunity is key to limiting the expansion of parasitic stages early in infection. One mechanism in which it does this is through the generation of early cytokines, such as IL-18. The processing and secretion of mature IL-18 (and IL-1ß) is mediated by caspase-1 which is activated within an inflammasome following the engagement of inflammasome-initiating sensors. We examined how the absence of caspase-1 and caspase-11, the adapter protein Asc, and other inflammasome components affects susceptibility to cryptosporidial infection by these and other key cytokines in the gut. We found that Casp-11-/-Casp-1-/- knockout mice have increased susceptibility to Cryptosporidium parvum infection as demonstrated by the 35-fold higher oocyst production (at peak infection) compared to wild-type mice. Susceptibility correlated with a lack of IL-18 in caspase-1 and caspase1/11 knockout mice, whereas IL-18 is significantly elevated in wildtype mice. IL-1ß was not generated in any significant amount following infection nor was any increased susceptibility observed in IL-1ß knockout mice. We also show that the adapter protein Asc is important to susceptibility, and that the caspase-1 canonical inflammasome signaling pathway is the dominant pathway in C. parvum resistance.


Subject(s)
CARD Signaling Adaptor Proteins/metabolism , Caspase 1/metabolism , Cryptosporidiosis/genetics , Cryptosporidiosis/metabolism , Cryptosporidium parvum/metabolism , Inflammasomes/metabolism , Animals , CARD Signaling Adaptor Proteins/deficiency , Caspase 1/deficiency , Caspases/deficiency , Caspases/metabolism , Caspases, Initiator , Cryptosporidium parvum/growth & development , Genetic Predisposition to Disease , Host-Parasite Interactions , Interleukin-18/metabolism , Mice , Mice, Knockout , Parasite Load , Signal Transduction
2.
Sci Rep ; 7: 42028, 2017 02 09.
Article in English | MEDLINE | ID: mdl-28181540

ABSTRACT

Triggering receptor expressed on myeloid cells-1(TREM-1) is a member of the superimmunoglobulin receptor family. We have previously shown that TREM-1 prolongs survival of macrophages treated with lipoolysaccharide through Egr2-Bcl2 signaling. Recent studies suggest a role for TREM-1 in viral immunity. Human immunodeficiency virus-1 (HIV) targets the monocyte/macrophage lineage at varying stages of infection. Emerging data suggest that macrophages are key reservoirs for latent HIV even in individuals on antiretroviral therapy. Here, we investigated the potential role of TREM-1 in HIV latency in macrophages. Our data show that human macrophages infected with HIV show an increased expression of TREM-1. In parallel, direct exposure to the HIV-related proteins Tat or gp120 induces TREM-1 expression in macrophages and confers anti-apoptotic attributes.NF-κB p65 silencing identified that these proteins induce TREM-1 in p65-dependent manner. TREM-1 silencing in macrophages exposed to HIV-related proteins led to increased caspase 3 activation and reduced Bcl-2 expression, rendering them susceptible to apotosis. These novel data reveal that TREM-1 may play a critical role in establishing HIV reservoir in macrophages by inhibiting apoptosis. Therefore, targeting TREM-1 could be a novel therapeutic approach to enhance clearance of the HIV reservoir, at least within the macrophage pools.


Subject(s)
HIV Envelope Protein gp120/metabolism , HIV Infections/virology , Host-Pathogen Interactions , Macrophages/virology , Triggering Receptor Expressed on Myeloid Cells-1/metabolism , Virus Latency , tat Gene Products, Human Immunodeficiency Virus/metabolism , Cell Survival , Cells, Cultured , Humans , Macrophages/physiology
3.
Am J Physiol Lung Cell Mol Physiol ; 310(5): L426-38, 2016 Mar 01.
Article in English | MEDLINE | ID: mdl-26684249

ABSTRACT

Triggering receptors expressed on myeloid cell-1 (TREM-1) is a superimmunoglobulin receptor expressed on myeloid cells. Synergy between TREM-1 and Toll-like receptor amplifies the inflammatory response; however, the mechanisms by which TREM-1 accentuates inflammation are not fully understood. In this study, we investigated the role of TREM-1 in a model of LPS-induced lung injury and neutrophilic inflammation. We show that TREM-1 is induced in lungs of mice with LPS-induced acute neutrophilic inflammation. TREM-1 knockout mice showed an improved survival after lethal doses of LPS with an attenuated inflammatory response in the lungs. Deletion of TREM-1 gene resulted in significantly reduced neutrophils and proinflammatory cytokines and chemokines, particularly IL-1ß, TNF-α, and IL-6. Physiologically deletion of TREM-1 conferred an immunometabolic advantage with low oxygen consumption rate (OCR) sparing the respiratory capacity of macrophages challenged with LPS. Furthermore, we show that TREM-1 deletion results in significant attenuation of expression of miR-155 in macrophages and lungs of mice treated with LPS. Experiments with antagomir-155 confirmed that TREM-1-mediated changes were indeed dependent on miR-155 and are mediated by downregulation of suppressor of cytokine signaling-1 (SOCS-1) a key miR-155 target. These data for the first time show that TREM-1 accentuates inflammatory response by inducing the expression of miR-155 in macrophages and suggest a novel mechanism by which TREM-1 signaling contributes to lung injury. Inhibition of TREM-1 using a nanomicellar approach resulted in ablation of neutrophilic inflammation suggesting that TREM-1 inhibition is a potential therapeutic target for neutrophilic lung inflammation and acute respiratory distress syndrome (ARDS).


Subject(s)
Lung Injury/drug therapy , Macrophages/drug effects , Membrane Glycoproteins/metabolism , MicroRNAs/genetics , Receptors, Immunologic/metabolism , Animals , Cytokines/metabolism , Inflammation/metabolism , Lipopolysaccharides/pharmacology , Lung Injury/metabolism , Macrophages/metabolism , Male , Mice, Inbred C57BL , Myeloid Cells/drug effects , Myeloid Cells/metabolism , Nanomedicine/methods , RNA, Small Interfering/metabolism , Triggering Receptor Expressed on Myeloid Cells-1
SELECTION OF CITATIONS
SEARCH DETAIL
...